Trial Profile

A pivotal Phase 3 trial for COVID-19-Influenza Combination (CIC) vaccine

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NanoFlu/NVX CoV 2373 combination vaccine-Novavax (Primary)
Indications COVID 2019 infections; Influenza virus infections
Focus Therapeutic Use

Most Recent Events

10 Dec 2024 According to a Novavax media release, first participant has been dosed in this trial
10 Dec 2024 Status changed from suspended to recruiting as per Novavax media release
11 Nov 2024 According to a Novavax media release, Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com